论文部分内容阅读
目的:观察前列地尔联合替米沙坦治疗早期糖尿病肾病的疗效。方法:早期糖尿病肾病患者66例随机分为观察组33例和对照组33例,在常规降糖治疗基础上,对照组给予替米沙坦80 mg,1次/d,口服;观察组给予前列地尔10μg+生理盐水100 mL静脉滴注,1次/d,替米沙坦用法用量同对照组。2组疗程均为14 d。比较2组治疗前、后24 h尿微量白蛋白、血肌酐、血尿素氮、空腹血糖。结果:2组治疗后24 h尿微量白蛋白、血肌酐水平均较治疗前下降(P<0.05),观察组下降优于对照组(P<0.05)。结论:前列地尔联合替米沙坦可降低早期糖尿病肾病患者24 h尿微量白蛋白水平,保护患者肾功能。
Objective: To observe the curative effect of alprostadil combined with telmisartan on early diabetic nephropathy. Methods: Sixty-six patients with early diabetic nephropathy were randomly divided into observation group (33 cases) and control group (33 cases). On the basis of routine hypoglycemic treatment, the control group was treated with telmisartan 80 mg once daily for observation. Dexter 10μg + saline 100 mL intravenous infusion, 1 / d, telmisartan usage amount with the control group. The two courses of treatment were 14 d. The urinary albumin, serum creatinine, blood urea nitrogen and fasting blood glucose in 24 hours before and after treatment were compared between two groups. Results: Urine microalbuminuria and serum creatinine were decreased 24 h after treatment in both groups (P <0.05), and the decrease in observation group was better than that in control group (P <0.05). Conclusion: Alprostadil combined with telmisartan can reduce 24 h urine microalbuminuria in patients with early diabetic nephropathy and protect renal function.